AbbVie Inc.
ABBV · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $314,351,300 | $273,986,960 | $286,211,310 | $239,658,000 |
| - Cash | $5,524,000 | $12,814,000 | $9,201,000 | $9,746,000 |
| + Debt | $67,841,000 | $60,120,000 | $64,191,000 | $77,575,000 |
| Enterprise Value | $376,668,300 | $321,292,960 | $341,201,310 | $307,487,000 |
| Revenue | $56,334,000 | $54,318,000 | $58,054,000 | $56,197,000 |
| % Growth | 3.7% | -6.4% | 3.3% | – |
| Gross Profit | $39,430,000 | $33,903,000 | $40,640,000 | $38,751,000 |
| % Margin | 70% | 62.4% | 70% | 69% |
| EBITDA | $14,910,000 | $17,172,000 | $24,174,000 | $23,933,000 |
| % Margin | 26.5% | 31.6% | 41.6% | 42.6% |
| Net Income | $4,278,000 | $4,863,000 | $11,836,000 | $11,542,000 |
| % Margin | 7.6% | 9% | 20.4% | 20.5% |
| EPS Diluted | 2.39 | 2.72 | 6.63 | 6.45 |
| % Growth | -12.1% | -59% | 2.8% | – |
| Operating Cash Flow | $18,806,000 | $22,839,000 | $24,943,000 | $22,777,000 |
| Capital Expenditures | -$974,000 | -$777,000 | -$695,000 | -$787,000 |
| Free Cash Flow | $17,832,000 | $22,062,000 | $24,248,000 | $21,990,000 |